ARTICLE | Financial News
Amgen tops consensus EPS
July 26, 2000 7:00 AM UTC
AMGN reported second quarter EPS of $0.28, beating the Street consensus by a penny, and up $0.03 over the 1999 quarter. Sales of Epogen erythropoietin to treat anemia were $493 million, a 15 percent increase over the $428 million sold in the 1999 quarter. Sales of Neupogen filgrastim to treat neutropenia were $310 million, a 2 percent increase over the $304 million sold in the 1999 quarter. ...